Dietary supplement for hair growth in men with androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the efficacy and safety of a dietary supplement, CL-P24113a, designed to manage androgenetic alopecia (AGA) in male participants aged 18 to 45 with mild to moderate hair loss. The supplement contains a blend of botanical ingredients, including Pumpkin Seed Oil and Saw Palmetto, aimed at inhibiting the 5α-reductase enzyme, which contributes to hair follicle miniaturization. In a single-blind, placebo-controlled design, 45 volunteers will be divided into two groups, with 30 receiving the supplement and 15 receiving a placebo. The study will assess the impact of the supplement on hair density and overall hair health over a six-month period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written consent for LOPD compliance.
* Written informed consent for study DC.506.36.117.
* Gender: Male.
* Age: Between 18 and 45 years.
* Diagnosis of alopecia with low hair density, classified as mild to moderate (stages II, III, and IV on the Hamilton-Norwood scale).

Willingness to have a 1-2 cm² area shaved throughout the study period.

* Last participation in a clinical study on hair health must have ended at least six months before the start of this study.
* 30-day washout period without specific hair treatments (using a neutral shampoo).
* No use of any other topical or oral hair treatments in the target area during the study period; if necessary, consultation with the principal investigator is required to evaluate continued study participation.

Exclusion Criteria:

* Individuals with gastrointestinal diseases (e.g., diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).
* Individuals with other physiological disorders (e.g., diabetes, hypertension, dyslipidemia) and/or gallstones.
* Individuals undergoing medical treatment in the weeks prior to the study that may interfere with study assessments (as determined by the investigator), particularly those who are currently taking or have taken 5α-reductase inhibitors (Finasteride, Dutasteride, Minoxidil, etc.) within the last three months.

Individuals who have undergone hair restoration treatments at any point in their lives, including hair transplants, mesotherapy, or platelet-rich plasma (PRP) therapy.

* Individuals following an atypical diet or planning to change their dietary routine during the study period.
* Individuals enrolled in another clinical study with similar characteristics (as determined by the investigator) during the study period.
* Individuals who are unable to fully understand the informed consent document or adhere to the study protocol.

Where it's running

• DermaClaim
  Valencia, Valencia, Spain Recruiting
• DermaClaim
  Valencia, Spain Recruiting

Study contacts

• Study coordinator: DermaClaim
• Email: dermaclaim@dermaclaim.com
• Phone: 96 187 45 82

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PP405 0.05% topically applied gel for adult men with pattern hair loss

  A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.

  Recruiting at 34 sites Phase 2/3 Pelage Pharmaceuticals, Inc. · Birmingham, Alabama and 62 other locations · NCT07819435

• EPI-001 for androgenetic alopecia in adults

  This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.

  Recruiting Phase 1/2 Epibiotech · Seoul, Seoul · NCT07618195

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• Secretome versus PRP injections to improve hair density in androgenetic alopecia

  This will try secretome injections versus platelet-rich plasma (PRP) injections to see which more effectively increases hair density and the terminal-to-vellus hair ratio in adults with androgenetic alopecia.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Denpasar, Bali · NCT07429253

• Fractional laser plus exosome vs. laser plus placebo for androgenetic alopecia

  This study tests whether adding a human umbilical cord mesenchymal stem cell exosome solution to fractional laser therapy helps men with androgenetic alopecia grow more hair than laser therapy with a placebo.

  Recruiting Chang Gung Memorial Hospital · Taoyuan, Taoyuan · NCT07248410

• Once-daily 5% minoxidil foam for female pattern hair loss

  This will try once-daily 5% minoxidil foam to see if it increases hair count in adult women with androgenetic alopecia compared with a placebo.

  Recruiting Phase 3 Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Beijing · NCT07080931

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.